Edition:
India

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

12.60USD
20 Jun 2019
Change (% chg)

$0.21 (+1.69%)
Prev Close
$12.39
Open
$12.59
Day's High
$12.75
Day's Low
$12.55
Volume
95,433
Avg. Vol
806,848
52-wk High
$17.60
52-wk Low
$8.28

Summary

Name Age Since Current Position

John Crowley

52 2011 Chairman of the Board and Chief Executive Officer

Bradley Campbell

43 2018 President, Chief Operating Officer, Director

Daphne Quimi

53 2019 Chief Financial Officer

Simon Jordan

2019 Senior Vice President - International

Jill Weimer

2019 Senior Vice President of Discovery Research and Gene Therapy Science

Samantha Prout

41 2018 Principal Accounting Officer, Global Controller

Hung Do

51 2015 Chief Scientific Officer

Jay Barth

55 2014 Chief Medical Officer

Ellen Rosenberg

56 2018 Chief Legal Officer and Corporate Secretary

Michael Raab

54 2018 Lead Independent Director

Lynn Bleil

55 2018 Independent Director

Robert Essner

71 2012 Independent Director

Ted Love

60 2012 Independent Director

Margaret McGlynn

59 2009 Independent Director

Glenn Sblendorio

63 2006 Independent Director

Craig Wheeler

58 2016 Independent Director

Biographies

Name Description

John Crowley

Mr. John F. Crowley J.D. is the Chairman of the Board and Chief Executive Officer of Amicus Therapeutics, Inc. Mr. Crowley has also served as a director of Amicus since August 2004, with the exception of the period from September 2006 to March 2007 when he was in active duty service in the United States Navy (Reserve). Mr. Crowley was President and Chief Executive Officer of Orexigen Therapeutics, Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals, Inc., from March 2000 until that company was acquired by Genzyme Corporation ("Genzyme") in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002. Mr. Crowley received a B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School.

Bradley Campbell

Mr. Bradley L. Campbell is President, Chief Operating Officer, Director of the Company. Mr. Campbell has served as a member of the Board since June 2018 and as President and Chief Operating Officer since January 2015. Mr. Campbell served as Chief Operating Officer since December 2013 and, prior thereto, as Chief Business Officer since February 2012. From January 2010 to February 2012, Mr. Campbell served as Senior Vice President, Business Operations; from May 2007 to January 2010, as Vice President, Business Planning and from April 2006 until May 2007, as Senior Director, Business Development. Mr. Campbell served as Senior Product Manager of Myozyme© for Pompe Disease and later as Business Director of CV Gene Therapy at Genzyme Corporation from 2002 to 2006. Mr. Campbell has also worked in sales & marketing for Bristol-Myers Squibb and as a business strategy consultant for Marakon Associates. Mr. Campbell is also a director for Progenics (NASDAQ: PGNX) and a board member of BioNJ. Mr. Campbell received his B.A. from Duke University and his M.B.A. from Harvard Business School. Mr. Campbell's significant experience within the pharmaceutical industry, much of which has been focused on rare diseases, and expertise in business operations, sales, marketing and product management, along with his service on the Board of Directors of another publicly-held biopharmaceutical company, all contributed to the Company's decision that he should be appointed a director of the Company as we continue our ongoing expansion as a fully integrated global commercial company.

Daphne Quimi

Ms. Daphne E. Quimi serves as Chief Financial Officer of Amicus Therapeutics Inc. Previously she served as Senior Vice President, Finance and has been employed with Amicus since September 2007. Prior to Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance department at Johnson & Johnson. Ms. Quimi brings extensive experience in public accounting and financial reporting. Ms. Quimi received a B.S. in Accountancy from Monmouth University and an M.B.A. from the Stern School of Business of New York University. She is a certified public accountant in New Jersey.

Simon Jordan

Mr. Simon Jordan is Senior Vice President - International of the Company. Mr. Jordan joins Amicus following a long-term tenure at Biogen (2005-2018). He most recently served as Regional Vice President, developing the business strategy and delivery of operational excellence across all therapy areas throughout multiple European Union (EU) and other international countries. He led the commercialization of Spinraza ® for spinal muscular atrophy across multiple geographies, including strategic leadership of pricing, reimbursement, pre-launch and launch activities which resulted in reimbursed launch in 11 countries within a 12-month period. Mr. Jordan also guided strategy development and implementation for Biogen's multiple sclerosis portfolio, with a focus on Tecfidera ® . Prior to Biogen, Mr. Jordan held roles of increasing responsibility within sales and marketing at Abbott.

Jill Weimer

Dr. Jill Weimer, Ph.D. is Senior Vice President of Discovery Research and Gene Therapy Science of the Company. For the last decade, Dr. Weimer has led a research team at Sanford Research in Sioux Falls, South Dakota focused on understanding the underlying biology behind neuropediatric disorders including various forms of Batten disease. More recently, she has overseen the management and development of the translational arm of Sanford Research. She will also continue to work with Sanford to support certain ongoing preclinical Batten disease programs in addition to her new role with Amicus. Dr. Weimer received her B.S. and Ph.D. in neuroscience from the University of Rochester. She completed her postdoctoral training in the Neuroscience Research Center at the University of North Carolina in Chapel Hill with a focus on developmental neuroscience before starting her lab at Sanford in 2009.

Samantha Prout

Ms. Samantha Whiteman Prout is Principal Accounting Officer, Global Controller of the Company. Prior to joining Amicus, Ms. Prout spent nearly three years at NRG Energy ("NRG"), first as Controller for Home Solar division, then as the Director of Financial Reporting. Prior to joining NRG, Ms. Prout spent over 15 years at KPMG LLP, the final nine as an Audit Senior Manager serving the life science practice in NJ. Ms. Prout received a Bachelor of Arts from Gettysburg College and is a certified public accountant.

Hung Do

Dr. Hung Viet Do Ph.D. serves as Chief Scientific Officer of the Company. Previously, he served as Senior Vice President, Discovery Biology since December 2013. Prior to joining Amicus, Dr. Do was a co-founder and Chief Scientific Officer of Callidus Biopharma, Inc. ("Callidus"), a privately held biologics company that was acquired by Amicus. Prior to founding Callidus, he headed early discovery research to decipher the mechanism of action for small molecule pharmacological chaperones at Amicus. He previously helped to demonstrate proof of concept for ERTs, and served as the project leader for a second generation Pompe ERT at Genzyme. Dr. Do also led molecular biology, cell culture and purification work and helped develop an in vitro protein modification process for improving drug targeting for protein therapeutics at Novazyme Pharmaceuticals, Inc., which was acquired by Genzyme. Dr. Do holds a Ph.D. in medical biochemistry and genetics from Texas A&M University and was a post-doctoral fellow in Hematology/Oncology at Emory University.

Jay Barth

Dr. Jay A. Barth M.D. serves as Chief Medical Officer of Amicus Therapeutics, Inc. Prior to joining Amicus, Dr. Barth held roles of increasing responsibility at PTC Therapeutics from 2009 to 2014. He most recently served as PTC Therapeutics' Senior Vice President, Clinical Development. Previously Dr. Barth served as Executive Director of Clinical Research at Merck; as Vice President, Clinical Research and Medical Affairs at Altana Pharma US, Inc.; and as Senior Director, Global Head of Gastroenterology Clinical Research at Eisai Medical Research Inc. Dr. Barth received a B.A. from Columbia University and an M.D. from the University of Pennsylvania School Of Medicine.

Ellen Rosenberg

Ms. Ellen S. Rosenberg serves as Chief Legal Officer and Corporate Secretary of the Company. She has served as our Chief Legal Officer and Corporate Secretary since December 2018 and our General Counsel and Corporate Secretary since February 2016. Prior to joining Amicus, she served as a Senior Vice President of Shire Pharmaceuticals. Prior to Shire, Ms. Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD Serono Inc., the U.S. affiliate of Merck KGaA. Ms. Rosenberg brings extensive and broad ranging legal experience in the biopharmaceutical and medical device industry including mergers and acquisitions, licensing, corporate governance, product launches, risk management, litigation, investigations and compliance matters. Ms. Rosenberg also has significant experience building and developing legal teams and the in-house legal function. Ms. Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Law School.

Michael Raab

Mr. Michael G. Raab is Lead Independent Director of Amicus Therapeutics, Inc. Mr. Raab has served as President and Chief Executive Officer of Ardelyx, Inc. (NASDAQ: ARDX) since March 2009. Mr. Raab previously served as a partner of New Enterprise Associates ("NEA") from June 2002 until December 2008, with a focus on healthcare investing. From 1999 to 2002, he was Senior Vice President, Therapeutics and General Manager, Renagel® at Genzyme Corporation. Mr. Raab currently serves as a member of the Board of Directors of Ardelyx, Inc. Mr. Raab holds a B.A. from DePauw University.

Lynn Bleil

Ms. Lynn Dorsey Bleil is Independent Director of the Company. Ms. Bleil led the West Coast Healthcare Practice of McKinsey & Company and was a core leader of McKinsey's worldwide Healthcare Practice before her retirement as a Senior Partner in 2013, after 25 years at the firm. Currently, Ms. Bleil serves as a member of the Board of Directors of Stericycle, Inc. (NASDAQ: SRCL), Sonova Holding AG (VX: SOON) and Alcon AG (NYSE:ALC). Her prior directorships included DST Systems, Inc. (NYSE: DST), and Auspex Pharmaceuticals (NASDAQ: ASPX). Ms. Bleil received her B.S.E. in Chemical Engineering from Princeton University and her M.B.A. from the Stanford Graduate School of Business.

Robert Essner

Mr. Robert A. Essner is an Independent Director of Amicus Therapeutics, Inc. Mr. Essner retired as Chairman and Chief Executive Officer of Wyeth Pharmaceuticals, Inc., now part of Pfizer Inc., in 2008. During his 32-year career in the pharmaceutical industry, he held several prominent leadership positions, including Chairman of the Pharmaceutical Research and Manufacturers Association. Prior to Wyeth, Mr. Essner spent more than a decade in various management positions at Sandoz Pharmaceuticals Corporation and as President of Sandoz Consumer Healthcare Group. Mr. Essner was formerly a Director at MassMutual Financial Group. He received a Bachelor's degree from Miami University and a Master's degree from the University of Chicago.

Ted Love

Dr. Ted W. Love M.D. is an Independent Director of Amicus Therapeutics, Inc. Dr. Love is currently the CEO of Global Blood Therapeutics, Inc. (NASDAQ: GBT). From February 2010 to August 2012, Dr. Love served as Executive Vice President and Head of Research and Development of Onyx Pharmaceuticals, Inc. From 2001 to 2009, Dr. Love was the President, Chief Executive Officer and Chairman of the Board of Directors of Nuvelo Inc. Before joining Nuvelo in 2001, he served as Senior Vice President of Development at Theravance, Inc. Prior to that, Dr. Love spent six years at Genentech, Inc. in a number of senior management positions in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as chairman of Genentech's Product Development Committee. In addition to Amicus, Dr. Love currently serves on the Board of Directors of Global Blood and was previously a board member of Cascadian Therapeutics. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.

Margaret McGlynn

Ms. Margaret G. McGlynn is an Independent Director of Amicus Therapeutics, Inc. She retired from Merck after 26 years including roles as President of Global Vaccines and Infectious Disease and President, U.S. Hospital and Specialty Products. She also served in a variety of executive leadership roles in global and U.S. marketing, sales and managed care. Following her retirement from Merck, Ms. McGlynn served as CEO and President of The International AIDS Vaccine Initiative. Currently, Ms. McGlynn serves as a member of the Boards of Directors of Air Products and Chemicals, Inc. (NYSE: APD) and Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX). She is also Chair of the Board of HCU Network America, a non-profit which provides advocacy and supports research for patients affected by the rare disease homocystinuria. Ms. McGlynn holds a B.S. in Pharmacy and a MBA in Marketing and an honorary doctorate in sciences from the State University of New York at Buffalo.

Glenn Sblendorio

Mr. Glenn P. Sblendorio is an Independent Director of Amicus Therapeutics, Inc. Since April 1, 2016, Mr. Sblendorio is currently Chief Executive Officer of IVERIC bio, Inc. (NASDAQ: ISEE), formerly Ophthotech Corporation (NASDAQ: OPHT) and is a member of the Board of Directors of IVERIC. Prior to IVERIC, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company (NASDAQ: MDCO) from March, 2006 through March, 2016 and was a member of the Board of Directors of the Medicines Company from July 2011 through December 31, 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Mr. Sblendorio also serves as a member of the Board of Directors of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (Chair, Audit). Mr. Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University.

Craig Wheeler

Mr. Craig A. Wheeler is an Independent Director of the Company. Since September 2006, Mr. Wheeler has served as President and Chief Executive Officer of Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA). At Momenta, Mr. Wheeler led the company through the launch of its first complex drug products. He has overseen the company's growth into the diversified business it is today. In 2011, he was an E&Y Entrepreneur of the Year Regional Award winner. In May 2012, the Boston Globe named Momenta the number one company in their annual Globe 100 survey of top performing companies. Prior to joining Momenta, Mr. Wheeler was President of Chiron Biopharmaceuticals where, during his five-year tenure, he led US and European commercial organizations and the pharmaceutical division's global sales more than doubled. Before that, he was a senior member of The Boston Consulting Group's health care practice and worked extensively in the health care sector with focus on pharma and biotech, particularly in regard to corporate and R&D strategy. He began his career at Merck & Company, Inc.'s (NYSE: MRK) MSDRL research unit. He also previously served as the Chairman of the Board of Avanir Pharmaceuticals, Inc. where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion. Mr. Wheeler received his BS and MS in chemical engineering from Cornell University and his MBA from the Wharton School of the University of Pennsylvania.

Basic Compensation

Name Fiscal Year Total

John Crowley

7,419,960

Bradley Campbell

2,828,650

Daphne Quimi

325,399

Simon Jordan

--

Jill Weimer

--

Samantha Prout

--

Hung Do

1,271,930

Jay Barth

2,092,240

Ellen Rosenberg

2,076,860

Michael Raab

257,268

Lynn Bleil

257,488

Robert Essner

199,708

Ted Love

209,708

Margaret McGlynn

217,208

Glenn Sblendorio

219,708

Craig Wheeler

204,708
As Of  31 Dec 2018